<DOC>
	<DOC>NCT01654640</DOC>
	<brief_summary>The purpose of this study is the evaluation of effect of metformin on obesity and metabolic disturbance in patients taking clozapine.</brief_summary>
	<brief_title>The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine</brief_title>
	<detailed_description>In this study, the investigators are going to examine the effect of metformin on obesity and metabolic disturbance in patients with schizophrenia who have taken clozapine.The metformin 500mg will be administrated per oral twice a day for 24 weeks and for control group, placebo will be given same route and process.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Age: 18 ~ 65 Patient with schizophrenia according to DSMIV criteria Patient have signed on the informed consent, and well understood the objective and procedure of this study. Patient taking clozapine 3months or more Patient increased in weight more than 10 % of that of before antipsychotics use Patient taking other antipsychotics with clozapine Patient in treatment of diabetes Patient in treatment of dyslipidemia Allergy or hypersensitivity to metformin Pregnant or breastfeeding female patient. Patient with severe medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>obesity</keyword>
	<keyword>clozapine</keyword>
	<keyword>metformin</keyword>
</DOC>